Evidence map›Paper›PMID 36853886›Full record

ArticleInfectious diseases (London, England)2023

Delays in fibrosis staging reduce the likelihood of achieving hepatitis C treatment and cure.

Austin T Jones, Lisa Moreno-Walton, Sierra D Sossamon, Fnu Tahmeena, Torrence Tran, Christopher Briones, Rachael Stevens, Katherine Isaacson, Hua He, Stacey Rhodes and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Austin T JonesDepartment of Emergency Medicine, Denver Health Medical Center, Denver, CO, USA.ORCID 0000-0002-0139-6807
Lisa Moreno-WaltonSection of Emergency Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Sierra D SossamonSection of Emergency Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Fnu TahmeenaDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Torrence TranDepartment of Emergency Medicine, University of California Los Angeles Medical Center, Los Angeles, CA, USA.
Christopher BrionesDepartment of Emergency Medicine, University of California Los Angeles Medical Center, Los Angeles, CA, USA.
Rachael StevensTulane University School of Medicine, New Orleans, LA, USA.
Katherine IsaacsonDepartment of Emergency Medicine, Emory University, Atlanta, GA, USA.
Hua HeDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Stacey RhodesSection of Emergency Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Jeffrey PercakTulane University School of Medicine, New Orleans, LA, USA.
Patricia J KissingerDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.ORCID 0000-0002-2038-9151
Tulane University · USLouisiana State University Health Sciences Center New Orleans · USUniversity of California, Los Angeles · USDenver Health Medical Center · USEmory University · US

Funding

UAB Center for Clinical and Translational Sciences (CCTS)TL1TR001418 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2015 to 2018
$2.1M
NCATS NIH HHS TL1 TR001418
6 · The paper itself

Abstract

backgroundUpdated 2021 hepatitis C virus (HCV) treatment guidelines no longer recommend fibrosis staging for treatment-naïve patients without cirrhosis; however, numerous US state Medicaid plans continue to restrict initiation of HCV therapy by fibrosis stage. The study objective was to determine whether delays from HCV diagnosis to fibrosis staging impact the likelihood of initiating/completing HCV treatment and achieving sustained virologic response (SVR).

methodsA retrospective cohort study was performed among patients diagnosed with chronic HCV by an urban US emergency department who subsequently underwent fibrosis staging. Time elapsed from HCV diagnosis to hepatic fibrosis staging was evaluated on the likelihood of treatment initiation, treatment completion and SVR.

resultsAmong fibrosis staging modalities, hepatic ultrasounds occurred more quickly following HCV diagnosis (3.5 months, IQR = 12.4 months), compared to FibroSure (8.5 months, IQR = 20.4 months) and FibroScan (9.9 months, IQR = 18.0 months) (

conclusionsDelays in hepatitis fibrosis staging were significantly associated with decreased likelihood of HCV treatment initiation and SVR.

Indexed as

Hepatitis CHepatitis C, ChronicAntiviral AgentsHepacivirusHumansLiver CirrhosisRetrospective StudiesSustained Virologic ResponseAntiviral Agentsdelays in carefibrosis stagingHepatitis Csustained virologic responsetreatment

Identifiers

PMID36853886
PMCPMC10284034
OpenAlexW4322616816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.